For people with atrial fibrillation (Afib), investigational abelacimab proved to be a potent dual factor XI/XIa inhibitor with much lower safety risks compared with a direct oral anticoagulant (DOAC), ...
The addition of anthracyclines to adjuvant taxane-based chemotherapy improved survival for certain high-risk patients with ...
Patients with atrial fibrillation are typically prescribed an anticoagulant, or blood thinner, to reduce the risk of stroke, but many may discontinue ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback